Radiopharmaceuticals company Telix Pharmaceuticals has provided its Q4 FY24 trading update, showing sustained revenue growth.

Acadia Pharmaceuticals ACAD announced that it has submitted a marketing authorization application (MAA) to the European ...

Shares in Neuren Pharmaceuticals rallied in morning trade, after ending Wednesday's session as the worst performing ASX 200 ...

ACADIA Pharmaceuticals Inc (ACAD) stock saw a decline, ending the day at $16.9 which represents a decrease of $-1.00 or -5.59% from the prior close of $17.9. The stock opened at $18.15 and touched a ...

"Acadia submits MAA to EMA for Rett syndrome therapy" was originally created and published by Pharmaceutical Technology, a ...

The market didn't like what this stock had to say this morning... The post Why did this $1.4 billion ASX 200 healthcare stock ...

Neuren's partner Acadia Pharmaceuticals submits marketing authorisation application in Europe for trofinetide for treatment ...

In a report released today, Jeffrey Hung from Morgan Stanley maintained a Hold rating on ACADIA Pharmaceuticals (ACAD – Research Report), with ...

Neuren Pharmaceuticals' Rett syndrome treatment, trofinetide, is a step closer to receiving regulatory approval in the ...

Acadia is playing for keeps. It's not just about crushing 2025 sales recordsit's about building a powerhouse. With a strong lineup of innovative therapies, a clear path to European revenues, and some ...

Analyst Jason Butler from JMP Securities reiterated a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report) and keeping the price ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for trofinetide for the ...